Hikma Seeks To Meet Demand For 503B Compounding In US
CEO Sets Out Strategy For Company’s New Sterile Injectable Compounding Unit
Executive Summary
Hikma has set out its expectations for a “gradual ramp-up” of the 503B sterile injectable compounding business that it has launched in the US this month, with CEO Siggi Olafsson explaining in detail the strategic rationale for the new business.
You may also be interested in...
Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.
Hikma Differentiates With Succinylcholine Chloride PFS
Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.
Hikma Will Push Harder To Make M&A Happen
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.